New Post has been published on Stock Markets Daily
New Post has been published on http://www.stockmarketsdaily.com/collaborating-ratings-on-collabrx-nasdaqclrx/11928/
Collaborating Ratings on CollabRx (NASDAQ:CLRX)
(adsbygoogle = window.adsbygoogle || []).push();
CollabRx, Inc. (NASDAQ:CLRX)Â [Trend Analysis] has been under the microscope of investors lately interest in this small cap stock. We have a look to see where the current broker following the stock is at with their sentiments on CLRX.
Analysis
CollabRx, Inc. (NASDAQ:CLRX) last traded at $1.12 after moving up 5.66% for the trading day. The company last released their quarterly earnings results on 11-12-14 for the period ended Sep-14. The company reported earnings of -$0.35 against a Zack’s research estimate of $0.01. This represents a -3600.00% surprise on the expected result.
The current average broker recommendation for CollabRx, Inc., according to Zack’s research, is 3.00, based on 1 broker ratings. With 1 being a strong buy and 5 being a strong sell, this means that on a consensus basis, analysts currently see CollabRx, Inc. as a hold. The 12 month target consensus price estimate among these analysts for CollabRx, Inc. is currently at $1.85.
Out of the 1 broker recommendations for CLRX, 0 recommend it as a strong buy, 0 as a buy, 1 as a hold 0 as a sell and 0 as a strong sell.
For the current quarter, the consensus analyst estimate for CollabRx, Inc. (NASDAQ:CLRX) is -$0.37, with analysts expecting year on year growth for the company of 27.45%
About CollabRx, Inc. (NASDAQ:CLRX)
CollabRx, Inc. uses cloud-based systems to inform healthcare decision-making. It develops products that inform treatment planning. The Company’s product, Therapy Finder(TM)-Professional, is a series of Web-based system applications available for melanoma, colorectal cancer, and lung cancer. CollabRx also provides project-based consulting to life science companies and develops proprietary and unique digital content. CollabRx Inc., formerly known as Tegal Corporation, is headquartered in San Francisco, California.
